Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.68 |
| ▸ | NPC1 | O15118 | 4/20 | 0.68 |
| ▸ | RAB9A | P51151 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.61 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.56 |
| ▸ | CDK2 | P24941 | 6/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.54 |
| ▸ | CDK1 | P06493 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31206921 | 0.87 | KMT2A (0.55) | SMN1; SMN2NPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL31206965 | 0.84 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL5835800 | 0.83 | CCNE1 (0.79) | SMN1; SMN2NPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL31207089 | 0.83 | WNT3A (0.56) | SMN1; SMN2NPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL31207127 | 0.81 | WNT3A (0.57) | SMN1; SMN2NPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL31206996 | 0.81 | PORCN (0.60) | SMN1; SMN2NPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL31207138 | 0.81 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL31207128 | 0.81 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL31207113 | 0.81 | WNT3A (0.55) | SMN1; SMN2NPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL31207181 | 0.81 | MEN1 (0.57) | SMN1; SMN2NPC1RAB9AKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133909-B2 | Heteroaromatic monoamides as orexinin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133909-B2 | Heteroaromatic monoamides as orexinin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133909-B2 | Heteroaromatic monoamides as orexinin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-03-13 | — | — | US | disclosed |
| CN-102066325-A | Heteroaromatic monoamides as orexin receptor antagonists | HOFFMANN LA ROCHE | 2011-05-18 | — | — | CN | disclosed |
| EP-2297102-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009153180-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009153180-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| US-20090312314-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090312314-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090312314-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312314-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | SMN1; SMN2 2018/4885NPC1 1723/4885RAB9A 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.